Kursprognose für PharmaCyte Biotech Inc (PMCB)PMCBPharmaCyte Biotech Inc

Alphio's PMCB stock price prediction model matches the current PharmaCyte Biotech Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.36 (+0.05%). The 1-week path is $0.39 (+7.13%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

PharmaCyte Biotech Inc (PMCB) appears to be a good buy right now due to its recent price performance and favorable technical indicators. The current price is $0.36, which is near the 52-week low of $0.30, indicating potential for upside as it has a 52-week high of $1.51. The stock has shown a 5-day change of +19.17%, suggesting a positive short-term momentum. Additionally, the forward P/E ratio is 7.02, indicating that the stock may be undervalued relative to its future earnings potential. However, a significant risk is the negative net income reported for the last quarter at -$4,873,411, which reflects ongoing financial challenges. Overall, the combination of a low entry price, potential for recovery, and positive short-term trends supports a buy recommendation.

PharmaCyte Biotech Inc (PMCB) last closed at $0.36, losing -4.05%. These facts feed the 1-day and 1-week PMCB price prediction above.